U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Chromophobe Renal Cell Carcinoma

MedGen UID:
1760698
•Concept ID:
C5419188
•
Neoplastic Process

Definition

Chromophobe renal cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAdvanced Chromophobe Renal Cell Carcinoma

Professional guidelines

PubMed

Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment.
Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M, Mafakher L
G Ital Nefrol 2022 Jun 20;39(3) PMID: 35819037
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A
J Natl Compr Canc Netw 2022 Jan;20(1):71-90. doi: 10.6004/jnccn.2022.0001. PMID: 34991070Free PMC Article
Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management.
Maher ER
World J Urol 2018 Dec;36(12):1891-1898. Epub 2018 Apr 21 doi: 10.1007/s00345-018-2288-5. PMID: 29680948Free PMC Article

Recent clinical studies

Etiology

The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges.
Mohanty SK, Lobo A, Cheng L
Hum Pathol 2023 Jun;136:123-143. Epub 2022 Sep 6 doi: 10.1016/j.humpath.2022.08.006. PMID: 36084769
Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment.
Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M, Mafakher L
G Ital Nefrol 2022 Jun 20;39(3) PMID: 35819037
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A
J Natl Compr Canc Netw 2022 Jan;20(1):71-90. doi: 10.6004/jnccn.2022.0001. PMID: 34991070Free PMC Article
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.
McDermott DF, Lee JL, Ziobro M, Suarez C, Langiewicz P, Matveev VB, Wiechno P, Gafanov RA, Tomczak P, Pouliot F, Donskov F, Alekseev BY, Shin SJ, Bjarnason GA, Castellano D, Silverman RK, Perini RF, Schloss C, Atkins MB
J Clin Oncol 2021 Mar 20;39(9):1029-1039. Epub 2021 Feb 2 doi: 10.1200/JCO.20.02365. PMID: 33529058Free PMC Article
Renal cell carcinoma.
Cairns P
Cancer Biomark 2010;9(1-6):461-73. doi: 10.3233/CBM-2011-0176. PMID: 22112490Free PMC Article

Diagnosis

Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma.
Rosellini M, Marchetti A, Mollica V, Rizzo A, Santoni M, Massari F
Nat Rev Urol 2023 Mar;20(3):133-157. Epub 2022 Nov 21 doi: 10.1038/s41585-022-00676-0. PMID: 36414800
Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment.
Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M, Mafakher L
G Ital Nefrol 2022 Jun 20;39(3) PMID: 35819037
Papillary renal cell carcinoma: current and controversial issues.
Angori S, Lobo J, Moch H
Curr Opin Urol 2022 Jul 1;32(4):344-351. Epub 2022 Jun 9 doi: 10.1097/MOU.0000000000001000. PMID: 35674688Free PMC Article
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A
J Natl Compr Canc Netw 2022 Jan;20(1):71-90. doi: 10.6004/jnccn.2022.0001. PMID: 34991070Free PMC Article
Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies.
Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, Kolenko VM
Mol Cancer Ther 2018 Jul;17(7):1355-1364. doi: 10.1158/1535-7163.MCT-17-1299. PMID: 29967214Free PMC Article

Therapy

Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A, Lefkowitz RA, Shapnik N, Dadoun C, Reznik E, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha R, Feldman DR, Motzer RJ
J Clin Oncol 2022 Jul 20;40(21):2333-2341. Epub 2022 Mar 17 doi: 10.1200/JCO.21.01944. PMID: 35298296Free PMC Article
HIF Inhibitors: Status of Current Clinical Development.
Fallah J, Rini BI
Curr Oncol Rep 2019 Jan 22;21(1):6. doi: 10.1007/s11912-019-0752-z. PMID: 30671662
Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies.
Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, Kolenko VM
Mol Cancer Ther 2018 Jul;17(7):1355-1364. doi: 10.1158/1535-7163.MCT-17-1299. PMID: 29967214Free PMC Article
Treatment of renal cell carcinoma: Current status and future directions.
Barata PC, Rini BI
CA Cancer J Clin 2017 Nov;67(6):507-524. Epub 2017 Sep 29 doi: 10.3322/caac.21411. PMID: 28961310
Renal cell carcinoma.
Jonasch E, Gao J, Rathmell WK
BMJ 2014 Nov 10;349:g4797. doi: 10.1136/bmj.g4797. PMID: 25385470Free PMC Article

Prognosis

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK
Lancet Oncol 2022 Jul;23(7):888-898. Epub 2022 Jun 7 doi: 10.1016/S1470-2045(22)00290-X. PMID: 35688173Free PMC Article
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A, Lefkowitz RA, Shapnik N, Dadoun C, Reznik E, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha R, Feldman DR, Motzer RJ
J Clin Oncol 2022 Jul 20;40(21):2333-2341. Epub 2022 Mar 17 doi: 10.1200/JCO.21.01944. PMID: 35298296Free PMC Article
Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review.
Roussel E, Capitanio U, Kutikov A, Oosterwijk E, Pedrosa I, Rowe SP, Gorin MA
Eur Urol 2022 May;81(5):476-488. Epub 2022 Feb 22 doi: 10.1016/j.eururo.2022.01.040. PMID: 35216855Free PMC Article
Renal cell carcinoma.
Jonasch E, Gao J, Rathmell WK
BMJ 2014 Nov 10;349:g4797. doi: 10.1136/bmj.g4797. PMID: 25385470Free PMC Article
Renal cell carcinoma.
Rini BI, Campbell SC, Escudier B
Lancet 2009 Mar 28;373(9669):1119-32. Epub 2009 Mar 5 doi: 10.1016/S0140-6736(09)60229-4. PMID: 19269025

Clinical prediction guides

Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma.
Rosellini M, Marchetti A, Mollica V, Rizzo A, Santoni M, Massari F
Nat Rev Urol 2023 Mar;20(3):133-157. Epub 2022 Nov 21 doi: 10.1038/s41585-022-00676-0. PMID: 36414800
Papillary renal cell carcinoma: current and controversial issues.
Angori S, Lobo J, Moch H
Curr Opin Urol 2022 Jul 1;32(4):344-351. Epub 2022 Jun 9 doi: 10.1097/MOU.0000000000001000. PMID: 35674688Free PMC Article
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A, Lefkowitz RA, Shapnik N, Dadoun C, Reznik E, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha R, Feldman DR, Motzer RJ
J Clin Oncol 2022 Jul 20;40(21):2333-2341. Epub 2022 Mar 17 doi: 10.1200/JCO.21.01944. PMID: 35298296Free PMC Article
Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, Segata N, Desnoyer A, Pietrantonio F, Ferrere G, Fahrner JE, Le Chatellier E, Pons N, Galleron N, Roume H, Duong CPM, Mondragón L, Iribarren K, Bonvalet M, Terrisse S, Rauber C, Goubet AG, Daillère R, Lemaitre F, Reni A, Casu B, Alou MT, Alves Costa Silva C, Raoult D, Fizazi K, Escudier B, Kroemer G, Albiges L, Zitvogel L
Eur Urol 2020 Aug;78(2):195-206. Epub 2020 May 4 doi: 10.1016/j.eururo.2020.04.044. PMID: 32376136
Renal Medullary Carcinoma.
Elliott A, Bruner E
Arch Pathol Lab Med 2019 Dec;143(12):1556-1561. Epub 2019 Mar 11 doi: 10.5858/arpa.2017-0492-RS. PMID: 30855171

Recent systematic reviews

First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E, Hornbach C, Dressen N, Goldkuhle M, Maisch P, Dahm P, Heidenreich A, Skoetz N
Cochrane Database Syst Rev 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2. PMID: 37146227Free PMC Article
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.
Cozma A, Sporis ND, Lazar AL, Buruiana A, Ganea AM, Malinescu TV, Berechet BM, Fodor A, Sitar-Taut AV, Vlad VC, Negrean V, Orasan OH
Int J Mol Sci 2022 Sep 19;23(18) doi: 10.3390/ijms231810948. PMID: 36142866Free PMC Article
Epidemiology of Renal Cell Carcinoma: 2022 Update.
Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, Kassouf W, Mitchell T, Montironi R, O'Brien T, Panebianco V, Scelo G, Shuch B, van Poppel H, Blosser CD, Psutka SP
Eur Urol 2022 Nov;82(5):529-542. Epub 2022 Sep 10 doi: 10.1016/j.eururo.2022.08.019. PMID: 36100483
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.
Wu Z, Chen Q, Qu L, Li M, Wang L, Mir MC, Carbonara U, Pandolfo SD, Black PC, Paul AK, Di Lorenzo G, Porpiglia F, Mari A, Necchi A, Rouprêt M, Psutka SP, Autorino R
Eur Urol 2022 Apr;81(4):414-425. Epub 2022 Jan 31 doi: 10.1016/j.eururo.2022.01.028. PMID: 35101302
Adjuvant therapy for locally advanced renal cell carcinoma: A meta-analysis and systematic review.
Bai Y, Li S, Jia Z, Ding Y, Gu C, Yang J
Urol Oncol 2018 Feb;36(2):79.e1-79.e10. Epub 2017 Oct 31 doi: 10.1016/j.urolonc.2017.10.001. PMID: 29110942

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...